These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 10889864)
1. Hereditary breast cancer. Identifying and managing BRCA1 and BRCA2 carriers. Heisey RE; Carroll JC; Warner E; McCready DR; Goel V Can Fam Physician; 1999 Jan; 45():114-24. PubMed ID: 10889864 [TBL] [Abstract][Full Text] [Related]
2. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145 [TBL] [Abstract][Full Text] [Related]
3. A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families. Machácková E; Foretová L; Navrátilová M; Valík D; Claes K; Messiaen L Cas Lek Cesk; 2000 Oct; 139(20):635-7. PubMed ID: 11192759 [TBL] [Abstract][Full Text] [Related]
11. Sex ratio distortion in offspring of families with BRCA1 or BRCA2 mutant alleles: an ascertainment bias phenomenon? Balmaña J; Díez O; Campos B; Majewski M; Sanz J; Alonso C; Baiget M; Garber JE Breast Cancer Res Treat; 2005 Aug; 92(3):273-7. PubMed ID: 16155798 [TBL] [Abstract][Full Text] [Related]
12. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589 [TBL] [Abstract][Full Text] [Related]
14. Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer. Kuschel B; Lux MP; Goecke TO; Beckmann MW Eur J Cancer Prev; 2000 Jun; 9(3):139-50. PubMed ID: 10954253 [TBL] [Abstract][Full Text] [Related]
15. Men at risk of being a mutation carrier for hereditary breast/ovarian cancer: an exploration of attitudes and psychological functioning during genetic testing. Lodder L; Frets PG; Trijsburg RW; Tibben A; Meijers-Heijboer EJ; Duivenvoorden HJ; Wagner A; van Der Meer CA; Devilee P; Cornelisse CJ; Niermeijer MF Eur J Hum Genet; 2001 Jul; 9(7):492-500. PubMed ID: 11464240 [TBL] [Abstract][Full Text] [Related]
16. Validation of a tool for identifying women at high risk for hereditary breast cancer in population-based screening. Hoskins KF; Zwaagstra A; Ranz M Cancer; 2006 Oct; 107(8):1769-76. PubMed ID: 16967460 [TBL] [Abstract][Full Text] [Related]
17. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1. Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ; J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670 [TBL] [Abstract][Full Text] [Related]
18. Tamoxifen as chemoprevention in BRCA1 and BRCA2 mutation carriers with breast cancer: a pilot survey of physicians. Peshkin BN; Isaacs C; Finch C; Kent S; Schwartz MD J Clin Oncol; 2003 Dec; 21(23):4322-8. PubMed ID: 14645421 [TBL] [Abstract][Full Text] [Related]
19. Public health aspects of breast cancer gene testing in Canada. Part 1: risks and interventions. Elwood JM Chronic Dis Can; 1999; 20(1):3-13. PubMed ID: 10352130 [TBL] [Abstract][Full Text] [Related]
20. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. Rebbeck TR; Friebel T; Lynch HT; Neuhausen SL; van 't Veer L; Garber JE; Evans GR; Narod SA; Isaacs C; Matloff E; Daly MB; Olopade OI; Weber BL J Clin Oncol; 2004 Mar; 22(6):1055-62. PubMed ID: 14981104 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]